A Phase II /III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum]

Clinical Ophthalmology, Dec 2018

A Phase II /III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum] Tauber J, Schechter BA, Bacharach J, et al. Clin Ophthalmol. 2018;12:1921–1929. On page 1924, Efficacy end points, Conjunctival staining section, the sentence “Statistically significant reductions in the mean change from baseline in the study eye at Day 84 relative to vehicle were observed for both OTX-101 concentrations (P

A PDF file should load here. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a PDF plug-in installed and enabled in your browser.

Alternatively, you can download the file locally and open with any standalone PDF reader:

https://www.dovepress.com/getfile.php?fileID=46985

A Phase II /III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum]

peer-reviewed journal covering all subspecialties within ophthalmology. Key topics include: Optometry A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum] Tauber J Schechter Bacharach J et al. Clin Ophthalmol. 8 1 0 2 - c e D - 1 2 n o 7 0 2 . 6 4 . 9 5 . 7 3 y b / m o c . - ttsph ropeF open access to scientific and medical research C O r r i g e n d u m in the least squares mean change from baseline in the study eye at Day 84 relative to vehicle were observed for both On page 1924, Efficacy end points, Conjunctival staining OTX-101 concentrations (P,0.01). The results by study section, the sentence ?Statistically significant reductions in visit are depicted in Figure 3.? the mean change from baseline in the study eye at Day 84 relative to vehicle were observed for both OTX-101 concenOn page 1926, Figure 3 and captions should be replaced as trations (P,0.01). The results by study visit are depicted in follows: (light blue diamonds) and OTX-101 0.09% group (dark blue circles). http://dx.doi.org/10.2147/OPTH.S196843


This is a preview of a remote PDF: https://www.dovepress.com/getfile.php?fileID=46985

Joseph Tauber, Barry A Schechter, Jason Bacharach, Melissa M Toyos, Robert Smyth-Medina, Sidney L Weiss, Jodi I Luchs. A Phase II /III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum], Clinical Ophthalmology, 2018, 2637-2638, DOI: 10.2147/OPTH.S196843